Placenta hydrolyzate Laennec. Comorbid pathology and its possibilities of its treatment

Abstract

In the presented report, a new hepatoprotector Laennec’ and its clinical possibilities are considered from the perspective of comorbid pathology. This is due to the fact that the drug was obtained from placenta hydrolyzate, contains eight growth factors that affect different pathogenetic links of many diseases. 575 patients with different pathologies were studied. Overall effectiveness ranged from 83 to 92 %. It is concluded that Laennec is an effective hepatoprotector. With its various growth factors, the drug can be successfully used in the treatment of comorbid pathology.